BioPharma Dive November 12, 2024
Trace Neuroscience aims to advance an RNA-binding therapy designed to preserve — and potentially improve — muscle function in people living with the nerve-destroying disorder.
Third Rock Ventures, the well-known backer of biotechnology companies, is leading a nine-figure fundraising round for a startup that aims to treat ALS by replacing broken genetic machinery.
The startup, Trace Neuroscience, launched Tuesday with $101 million from an investment group that includes Atlas Venture, RA Capital Management and Alphabet’s venture capital arm, GV. Third Rock led the round and two of its partners, Jeffrey Tong and Dodzie Sogah, will sit on the company’s seven-member board of directors.
Based in the San Francisco area, Trace’s research centers on a molecule essential for processing RNA —...
Today's Sponsors
Today's Sponsor